Multicenter phase 2 trial reveals favorable resection rates in advanced hepatocellular carcinoma, suggesting preoperative lenvatinib is safe and feasible for unresectable disease.
The relatively high surgical resection rate seen in this study suggests the safety and feasibility of lenvatinib therapy followed by surgical resection for patients with oncologically or technically unresectable HCC.
No takes yet. Share an insight, caveat, or question.
Ichida et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: